Basic study for development of a novel therapeutic strategy, targeting the extracellular ATP hydrolyzing enzyme, CD39 to protect from vascular endothelial disorder.
Project/Area Number |
20590088
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Biological pharmacy
|
Research Institution | Takasaki University of Health and Welfare |
Principal Investigator |
MATSUOKA Isao Takasaki University of Health and Welfare, 薬学部, 教授 (10145633)
|
Co-Investigator(Kenkyū-buntansha) |
YOMOGIDA Sinnichi 高崎健康福祉大学, 薬学部, 准教授 (90250802)
|
Project Period (FY) |
2008 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 心血管 / 炎症 / 病態生理 / 細胞内情報伝達 / 血管内皮細胞 / 細胞外ヌクレオチド代謝 / CD39 / 遺伝子発現 / HMG-CoA還元酵素阻害剤 / PI3-キナーゼ / Akt / HIF-1α / P2受容体 / 炎症性サイトカイン / プロモーター解析 |
Research Abstract |
Vascular endothelial cells express highly active ecto-nucleoside diphosphohydrolase 1 (CD39) that hydrolyzes extracellular ATP and ADP into AMP. CD39 plays a critical role in the regulation of vascular homeostasis. In this study, we found that various inflammatory cytokines including IL-1β, TNF-α and IFN-γ, impaired the ATP hydrolysis and CD39 mRNA expression, whereas HMG-CoA reductase inhibitor (statin) caused time- and concentration-dependent increase in ATP and ADP hydrolysis accompanied by an up-regulation of CD39 mRNA expression. Statin-induced up-regulation of CD39 mRNA expression was involved in an inhibition of small G protein Rho function. These results suggest that the inhibition of Rho-dependent signaling is a promising strategy to increases vascular CD39 expression.
|
Report
(4 results)
Research Products
(33 results)